Kuros Biosciences AG

Kuros Biosciences is engaged in the discovery, development, and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases in Switzerland, and the United States. Co. develops Immunodrugs, a class of biopharmaceutical products that are intended for use in the prevention and treatment of chronic diseases, as well as to activate the patient's immune system to induce specific antibody and targeted T cell responses to modulate chronic disease processes. Co.'s product candidate, NIC002, is in Phase II clinical trials and is intended for the treatment of nicotine addiction.
  • TickerKURN
  • ISINCH0325814116
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland

Analysts

MarketLine Department

Actelion Ltd - Strategy, SWOT and Corporate Finance Report

Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Actelion Ltd. (Actelion or 'the company') is a biopharmaceutical company focused on the discovery, development and commercialization of low molecular weight drugs to address high unmet medical needs. The company classifies its business into single segment, which primarily focuses on discovery, ...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior